TABLE 2B.
Treatment exposure (PP)
| Group B (N ＝ 201) | Group C (N ＝ 198) | P | |
|---|---|---|---|
| Total number of cycles | 1177 | 1200 | |
| Cycles with delayed schedule | 279 (24%) | 208 (17%) | .29 |
| Because of neutropenia | 81 (29%) | 44 (21%) | |
| Because of leukopenia | 72 (26%) | 32 (15%) | |
| cycles with dose modification | 129 | 111 | .41 |
| Because of neutropenia | 64 (50%) | 51 (46%) | |
| Because of leukopenia | 52 (40%) | 46 (41%) | |
| Relative dose intensity | <.0001 | ||
| Oxaliplatin (median [%]) | 118.4 (91%) | 126.1 (97) | |
| S‐1 or capecitabine (median [%]) | 75.4 (94%) | 1925.4 (96%) | |
Data are n (％).